Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy
Rohan Mital, BS,
Alexander M. Cartron, MD,
John C. Trinidad, MD, MPH,
Natalie Spaccarelli, MD,
I-sanna Gibbons-Fideler, MD,
Benjamin H. Kaffenberger, MD, MS,
Catherine G. Chung, MD
Affiliations
Rohan Mital, BS
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Alexander M. Cartron, MD
Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland
John C. Trinidad, MD, MPH
Department of Dermatology, Massachusetts General Hospital, Cambridge, Massachusetts
Natalie Spaccarelli, MD
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio
I-sanna Gibbons-Fideler, MD
Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Benjamin H. Kaffenberger, MD, MS
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio
Catherine G. Chung, MD
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, Ohio; Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio; Correspondence to: Catherine G. Chung, MD, 2050 Kenny Rd MMT 930, Columbus, OH 43221.